Ikarian Capital, LLC Terns Pharmaceuticals, Inc. Transaction History

Ikarian Capital, LLC

$714 Million
Q1 2025

A detailed history of Ikarian Capital, LLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 308,491 shares of TERN stock, worth $937,812. This represents 0.12% of its overall portfolio holdings.

Number of Shares

308,491

Previous 308,491 -0.0%

Holding current value

$937,812

Previous $1.72 Million 50.55%

% of portfolio

0.12%

Previous 0.28%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$5.53 - $8.36 $33 - $50	-6 Reduced -0.0%	308,491 $1.72 Million
Q3 2024 Nov 14, 2024	SELL	$6.49 - $10.8 $973,500 - $1.62 Million	-150,000 Reduced 32.72%	308,497 $2.57 Million
Q2 2024 Aug 14, 2024	BUY	$4.54 - $8.2 $1.68 Million - $3.03 Million	370,000 Added 418.09%	458,497 $3.12 Million
Q1 2024 May 15, 2024	SELL	$4.86 - $8.19 $374,137 - $630,490	-76,983 Reduced 46.52%	88,497 $580,000
Q3 2023 Nov 14, 2023	SELL	$4.7 - $8.55 $705,000 - $1.28 Million	-150,000 Reduced 47.55%	165,480 $832,000
Q2 2023 Aug 14, 2023	SELL	$7.35 - $13.29 $2.98 Million - $5.39 Million	-405,861 Reduced 56.26%	315,480 $2.76 Million
Q1 2023 May 15, 2023	SELL	$7.91 - $12.0 $126,385 - $191,736	-15,978 Reduced 2.17%	721,341 $8.54 Million
Q4 2022 Feb 14, 2023	SELL	$4.62 - $10.18 $770,616 - $1.7 Million	-166,800 Reduced 18.45%	737,319 $7.51 Million
Q3 2022 Nov 14, 2022	BUY	$1.87 - $6.42 $381,702 - $1.31 Million	204,119 Added 29.16%	904,119 $5.33 Million
Q2 2022 Aug 12, 2022	BUY	$1.5 - $3.0 $1.05 Million - $2.1 Million	700,000 New	700,000 $1.74 Million

Others Institutions Holding TERN

# of Institutions

143

Shares Held

84.5M

Call Options Held

256K

Put Options Held

133K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $114M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Account

Ikarian Capital, LLC Terns Pharmaceuticals, Inc. Transaction History